PE20090998A1 - Inhibidores de mapk/erk quinasa - Google Patents
Inhibidores de mapk/erk quinasaInfo
- Publication number
- PE20090998A1 PE20090998A1 PE2008001910A PE2008001910A PE20090998A1 PE 20090998 A1 PE20090998 A1 PE 20090998A1 PE 2008001910 A PE2008001910 A PE 2008001910A PE 2008001910 A PE2008001910 A PE 2008001910A PE 20090998 A1 PE20090998 A1 PE 20090998A1
- Authority
- PE
- Peru
- Prior art keywords
- fluoro
- iodophenylamine
- tetrahydroindolizin
- halo
- oxo
- Prior art date
Links
- 102000043136 MAP kinase family Human genes 0.000 title abstract 3
- 108091054455 MAP kinase family Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- CUMTUBVTKOYYOU-UHFFFAOYSA-N 2-fluoro-4-iodoaniline Chemical compound NC1=CC=C(I)C=C1F CUMTUBVTKOYYOU-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Chemical group 0.000 abstract 1
- -1 IMINO Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- FZTCJYJKHSXPEX-UHFFFAOYSA-N n-hydroxysulfamide Chemical group NS(=O)(=O)NO FZTCJYJKHSXPEX-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98727907P | 2007-11-12 | 2007-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090998A1 true PE20090998A1 (es) | 2009-08-12 |
Family
ID=40340592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001910A PE20090998A1 (es) | 2007-11-12 | 2008-11-12 | Inhibidores de mapk/erk quinasa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8022057B2 (enExample) |
| EP (1) | EP2227469B9 (enExample) |
| JP (1) | JP5453290B2 (enExample) |
| AR (1) | AR069462A1 (enExample) |
| CA (1) | CA2705452C (enExample) |
| CL (1) | CL2008003366A1 (enExample) |
| ES (1) | ES2456966T3 (enExample) |
| PE (1) | PE20090998A1 (enExample) |
| TW (1) | TW200934775A (enExample) |
| WO (1) | WO2009064675A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| MX2009004269A (es) | 2006-10-23 | 2009-08-12 | Takeda Pharmaceutical | Inhibidores de cinasa mapk/erk. |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| PE20100747A1 (es) * | 2008-04-21 | 2010-11-03 | Novartis Ag | Compuestos heterociclicos como inhibidores de mek |
| EP2331136B1 (en) | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP2421612A1 (en) * | 2009-04-21 | 2012-02-29 | Novartis AG | Heterocyclic compounds as mek inhibitors |
| BR112012010519A2 (pt) * | 2009-11-04 | 2017-12-05 | Novartis Ag | derivados de sulfonamida heterocíclicos |
| WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
| CN101747300B (zh) * | 2009-12-22 | 2012-11-07 | 上海大学 | 基于紫杉醇和氮芥的协同前药及其制备方法 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| US9273054B2 (en) * | 2011-07-27 | 2016-03-01 | Glaxo Group Limited | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| CA3079071C (en) | 2012-10-19 | 2022-06-07 | Array Biopharma Inc. | Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| US9216163B2 (en) | 2013-05-20 | 2015-12-22 | Kyorin Pharmaceutical Co., Ltd. | Method of inhibiting angiogenesis |
| WO2014204263A1 (en) * | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| BR112017000672A2 (pt) | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
| WO2017058007A1 (en) | 2015-10-01 | 2017-04-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| WO2020036852A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| CN111662282B (zh) * | 2019-03-07 | 2021-07-06 | 湖南化工研究院有限公司 | 氮杂环并吡啶类化合物及其中间体 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0670044B2 (ja) * | 1987-11-20 | 1994-09-07 | キッセイ薬品工業株式会社 | ４ｈ―キノリジン―４―オン誘導体 |
| AU616916B2 (en) | 1987-11-20 | 1991-11-14 | Kissei Pharmaceutical Co. Ltd. | 4h-quinolizin-4-one compounds exhibiting therapeutic activities |
| AU5610398A (en) | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| CA2532067C (en) | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| KR101190912B1 (ko) * | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법 |
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| EP1838675A1 (en) | 2004-11-24 | 2007-10-03 | Laboratoires Serono S.A. | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| ES2330872T3 (es) | 2004-12-01 | 2009-12-16 | Merck Serono Sa | Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas. |
| TWI441637B (zh) * | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Ｍｅｋ雜環抑制劑及其使用方法 |
| MX2009004269A (es) | 2006-10-23 | 2009-08-12 | Takeda Pharmaceutical | Inhibidores de cinasa mapk/erk. |
| EP2113500A1 (en) | 2006-10-31 | 2009-11-04 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| PE20100747A1 (es) * | 2008-04-21 | 2010-11-03 | Novartis Ag | Compuestos heterociclicos como inhibidores de mek |
| EP2421612A1 (en) | 2009-04-21 | 2012-02-29 | Novartis AG | Heterocyclic compounds as mek inhibitors |
-
2008
- 2008-11-07 US US12/267,353 patent/US8022057B2/en active Active
- 2008-11-07 ES ES08849376.2T patent/ES2456966T3/es active Active
- 2008-11-07 CA CA2705452A patent/CA2705452C/en not_active Expired - Fee Related
- 2008-11-07 EP EP08849376.2A patent/EP2227469B9/en active Active
- 2008-11-07 WO PCT/US2008/082846 patent/WO2009064675A1/en not_active Ceased
- 2008-11-07 JP JP2010533285A patent/JP5453290B2/ja active Active
- 2008-11-11 TW TW097143569A patent/TW200934775A/zh unknown
- 2008-11-12 PE PE2008001910A patent/PE20090998A1/es not_active Application Discontinuation
- 2008-11-12 CL CL2008003366A patent/CL2008003366A1/es unknown
- 2008-11-12 AR ARP080104939A patent/AR069462A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2456966T3 (es) | 2014-04-24 |
| AR069462A1 (es) | 2010-01-27 |
| EP2227469B9 (en) | 2014-09-10 |
| EP2227469B1 (en) | 2014-01-08 |
| JP5453290B2 (ja) | 2014-03-26 |
| WO2009064675A1 (en) | 2009-05-22 |
| US8022057B2 (en) | 2011-09-20 |
| JP2011503099A (ja) | 2011-01-27 |
| CA2705452C (en) | 2016-05-31 |
| CA2705452A1 (en) | 2009-05-22 |
| TW200934775A (en) | 2009-08-16 |
| CL2008003366A1 (es) | 2009-05-29 |
| US20090124595A1 (en) | 2009-05-14 |
| EP2227469A1 (en) | 2010-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099525A (es) | Inhibidores de mek | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20120370A1 (es) | Derivados de 2,4-diaminopirimidinas como inhibidores de ptk2 | |
| EA201200653A1 (ru) | Гетариламинохинолины | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| EA201070619A1 (ru) | Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| PE20090071A1 (es) | Inhidibores de mapk/erk quinasa | |
| EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| PE20141405A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| MX2022014444A (es) | Sal de malato de n-(4-{[6,7-bis(metiloxi) quinolin-4-il] oxi}fenil)-n'-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer. | |
| EA200870446A1 (ru) | Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов мек | |
| PE20130647A1 (es) | Indoles | |
| CY1113560T1 (el) | Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων | |
| ATE432272T1 (de) | Aminophenylderivate als neue inhibitoren von histondeacetylase | |
| CO6160235A2 (es) | Isoxazolinas insecticidas | |
| AR065845A1 (es) | Quinolonas y tetrahidroquinolinas y compuestos relacionados con actividad inhibidoria de nos | |
| EA200702568A1 (ru) | Гетеробициклические ингибиторы металлопротеазы и их применение | |
| EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
| NO20090628L (no) | Pyridizinon derivativater | |
| EA200901124A1 (ru) | Соединения формулы (i) в качестве ингибиторов серинпротеазы | |
| EA201792052A1 (ru) | Соли амидов n-(1,3,4-оксадиазол-2-ил)арил карбоновой кислоты и их применение в качестве гербицидов | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| PE20081468A1 (es) | Derivados de tetrahidropirimidin-5-carboxamida como inhibidores de mapk/erk quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |